Health Care & Life Sciences » Pharmaceuticals | Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc. | Ownership

Companies that own Gemphire Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Cormorant Asset Management LP
1,041,635
7.3%
0
0.1%
06/30/2018
NorthPointe Capital LLC
698,802
4.9%
-80,307
0.13%
06/30/2018
Exchange Capital Management, Inc.
532,381
3.73%
-3,900
0.21%
06/30/2018
BAMCO, Inc.
469,860
3.29%
-40,789
0%
06/30/2018
The Vanguard Group, Inc.
378,791
2.66%
3,760
0%
06/30/2018
Millennium Management LLC
194,436
1.36%
194,436
0%
06/30/2018
Cambridge Investment Research Advisors, Inc.
167,364
1.17%
400
0%
06/30/2018
Wilks Brothers LLC
158,547
1.11%
158,547
0.02%
06/30/2018
Marshall Wace North America LP
145,875
1.02%
145,875
0%
06/30/2018
Stonepine Capital Management LLC
103,000
0.72%
-139,812
0.08%
06/30/2018

About Gemphire Therapeutics

View Profile
Address
17199 North Laurel Park Drive
Livonia Michigan 48152
United States
Employees -
Website http://www.gemphire.com
Updated 07/08/2019
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.